Bioasis Technologies Inc., of Richmond, British Columbia, and Bioagilytix Labs Inc., of Durham, N.C., disclosed a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, Bioasis’ lead candidate to treat HER2-positive brain cancer, to IND submission and into the clinic.